Evidence map›Paper›PMID 34194477›Full record

ArticleFrontiers in genetics2021

Development of an Immune-Related LncRNA Prognostic Signature for Glioma.

Yudong Cao, Hecheng Zhu, Jun Tan, Wen Yin, Quanwei Zhou, Zhaoqi Xin, Zhaoping Wu, Zhipeng Jiang, Youwei Guo, Yirui Kuang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Crosstalk betweenInternational journal of molecular sciences · 2023
    Review
  6. Article
  7. Effects ofFrontiers in genetics · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yudong CaoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Hecheng ZhuChangsha Kexin Cancer Hospital, Changsha, China.
Jun TanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Wen YinDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Quanwei ZhouDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zhaoqi XinDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zhaoping WuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zhipeng JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Youwei GuoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yirui KuangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Can LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Ming ZhaoChangsha Kexin Cancer Hospital, Changsha, China.
Xingjun JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Jiahui PengDepartment of Medical Ultrasonics, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Caiping RenKey Laboratory for Carcinogenesis of Chinese Ministry of Health, School of Basic Medical Science, Cancer Research Institute, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNThe Seventh Affiliated Hospital of Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGlioma is the most common primary cancer of the central nervous system with dismal prognosis. Long noncoding RNAs (lncRNAs) have been discovered to play key roles in tumorigenesis in various cancers, including glioma. Because of the relevance between immune infiltrating and clinical outcome of glioma, identifying immune-related lncRNAs is urgent for better personalized management. MATERIALS AND

methodsSingle-sample gene set enrichment analysis (ssGSEA) was applied to estimate immune infiltration, and glioma samples were divided into high immune cell infiltration group and low immune cell infiltration group. After screening differentially expressed lncRNAs in two immune groups, least absolute shrinkage and selection operator (LASSO) Cox regression analysis was performed to construct an immune-related prognostic signature. Additionally, we explored the correlation between immune infiltration and the prognostic signature.

resultsA total of 653 samples were appropriate for further analyses, and 10 lncRNAs were identified as immune-related lncRNAs in glioma. After univariate Cox regression and LASSO Cox regression analysis, six lncRNAs were identified to construct a prognostic signature for glioma, which could be taken as independent prognostic factors in both univariate and multivariate Cox regression analyses. Moreover, risk score was significantly correlated with all the 29 immune-related checkpoint expression (

conclusionThe study constructed an immune-related prognostic signature for glioma, which contributed to improve clinical outcome prediction and guide immunotherapy.

Indexed as

gliomaimmune signaturelncRNArisk scoreTCGA

Identifiers

PMID34194477
PMCPMC8238205
OpenAlexW3166593194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.